Augmented Concentration of Isopentyl-Deoxynyboquinone in Tumors Selectively Kills NAD(P)H Quinone Oxidoreductase
Jiangwei Wang1, Xiaolin Su2, Lingxiang Jiang1
1Department of Radiation Oncology, Indianapolis, IN 46202, USA.
Abstract:
Lung and breast cancers rank as two of the most common and lethal tumors, accounting for a substantial number of cancer-related deaths worldwide. While the past two decades have witnessed promising progress in tumor therapy, developing targeted tumor therapies continues to pose a significant challenge. NAD(P)H quinone oxidoreductase 1 (NQO1), a two-electron reductase, has been reported as a promising therapeutic target across various solid tumors. β-Lapachone (β-Lap) and deoxynyboquinone (DNQ) are two NQO1 bioactivatable drugs that have demonstrated potent antitumor effects. However, their curative efficacy has been constrained by adverse effects and moderate lethality. To enhance the curative potential of NQO1 bioactivatable drugs, we developed a novel DNQ derivative termed isopentyl-deoxynyboquinone (IP-DNQ). Our study revealed that IP-DNQ treatment significantly increased reactive oxygen species generation, leading to double-strand break (DSB) formation, PARP1 hyperactivation, and catastrophic energy loss. Notably, we discovered that this novel drug induced both apoptosis and programmed necrosis events, which makes it entirely distinct from other NQO1 bioactivatable drugs. Furthermore, IP-DNQ monotherapy demonstrated significant antitumor efficacy and extended mice survival in A549 orthotopic xenograft models. Lastly, we identified that in mice IP-DNQ levels were significantly elevated in the plasma and tumor compared with IB-DNQ levels. This study provides novel preclinical evidence supporting IP-DNQ efficacy in NQO1 NSCLC and breast cancer cells.
Insights
A new drug, isopentyl-deoxynyboquinone (IP-DNQ), effectively targets NQO1-positive lung and breast cancers by inducing cell death. IP-DNQ shows promise as a potent cancer therapy with improved efficacy and drug levels in preclinical models.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Lung and breast cancers are leading causes of cancer deaths globally.
- NAD(P)H quinone oxidoreductase 1 (NQO1) is a validated therapeutic target in solid tumors.
- Existing NQO1 bioactivatable drugs like β-Lapachone and deoxynyboquinone have limitations in efficacy and toxicity.
Purpose of the Study:
- To develop a novel NQO1 bioactivatable drug with enhanced antitumor potential.
- To investigate the mechanism of action of the new drug, isopentyl-deoxynyboquinone (IP-DNQ).
- To evaluate the preclinical efficacy of IP-DNQ in NQO1-expressing cancers.
Main Methods:
- Synthesis and characterization of the novel DNQ derivative, IP-DNQ.
- Assessment of IP-DNQ's effects on reactive oxygen species (ROS) generation, DNA damage (DSBs), and PARP1 activation.
- Evaluation of cell death pathways (apoptosis and programmed necrosis) induced by IP-DNQ.
- In vivo efficacy studies using A549 orthotopic xenograft models in mice.
- Pharmacokinetic analysis of IP-DNQ levels in plasma and tumor tissues.
Main Results:
- IP-DNQ significantly increased ROS generation and induced DNA double-strand breaks.
- The drug triggered PARP1 hyperactivation and catastrophic energy loss in cancer cells.
- IP-DNQ uniquely induced both apoptosis and programmed necrosis, differentiating it from other NQO1 drugs.
- IP-DNQ monotherapy demonstrated significant antitumor activity and improved survival in preclinical models.
- Elevated IP-DNQ levels were observed in plasma and tumor tissues compared to controls.
Conclusions:
- IP-DNQ represents a novel NQO1 bioactivatable drug with potent antitumor activity.
- Its unique dual mechanism of inducing apoptosis and necrosis offers a distinct therapeutic advantage.
- Preclinical data support IP-DNQ's efficacy in NQO1-positive non-small cell lung cancer (NSCLC) and breast cancer.
- IP-DNQ warrants further investigation as a potential targeted therapy for these cancers.
More Related Videos
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...